[Antihypertensive treatment after apoplexy--protective effects against cardiovascular disease in addition to reduction of blood pressure?].
The presence of significant effects beyond what may be achieved by reducing consultation blood pressure, particularly in stroke prevention, has been indicated by several clinical hypertension trials, including LIFE, ASCOT, NORDIL, ACCESS and now also MOSES. New data suggest that apparent pressure equality could be a beta-blocker-induced diminished white coat effect; despite this, the evidence points towards the presence, however not a major one, of meaningful preventive effects unrelated to pressure reduction.